What is Roth Capital’s Estimate for SPRY Q3 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at Roth Capital issued their Q3 2025 EPS estimates for ARS Pharmaceuticals in a research report issued on Thursday, September 4th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of ($0.44) per share for the quarter. Roth Capital has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals’ Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.63) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.77 EPS, FY2028 earnings at $2.06 EPS and FY2029 earnings at $4.06 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.05). The business had revenue of $15.72 million during the quarter, compared to the consensus estimate of $12.92 million. ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%.

Separately, Wall Street Zen lowered shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.50.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $10.32 on Monday. The company’s fifty day simple moving average is $15.65 and its 200-day simple moving average is $14.35. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37. The firm has a market cap of $1.02 billion, a PE ratio of -21.06 and a beta of 0.87. ARS Pharmaceuticals has a 12 month low of $9.97 and a 12 month high of $18.90.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Sarina Tanimoto sold 37,656 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $14.09, for a total value of $530,573.04. Following the transaction, the insider directly owned 1,247,447 shares in the company, valued at approximately $17,576,528.23. This represents a 2.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder James E. Flynn sold 740,149 shares of the company’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total transaction of $13,663,150.54. Following the completion of the transaction, the insider owned 4,887,254 shares in the company, valued at $90,218,708.84. This trade represents a 13.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 882,649 shares of company stock valued at $15,773,760. Corporate insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SPRY. Dimensional Fund Advisors LP lifted its position in ARS Pharmaceuticals by 2.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 196,458 shares of the company’s stock worth $2,073,000 after purchasing an additional 4,010 shares during the period. Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals by 5.7% in the fourth quarter. Northern Trust Corp now owns 478,153 shares of the company’s stock worth $5,045,000 after acquiring an additional 25,773 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of ARS Pharmaceuticals by 113.8% in the fourth quarter. Ameriprise Financial Inc. now owns 69,376 shares of the company’s stock worth $732,000 after acquiring an additional 36,928 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $75,000. Finally, Balyasny Asset Management L.P. lifted its holdings in shares of ARS Pharmaceuticals by 1,431.8% in the fourth quarter. Balyasny Asset Management L.P. now owns 344,941 shares of the company’s stock worth $3,639,000 after acquiring an additional 322,423 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.